Form 4: Aspira Women's Health Director Converts Vested Restricted Stock Units into Common Stock

Aspira Women's Health Inc. Director Jannie Herchuk converted 8,437 vested restricted stock units into common stock on June 4, 2025, increasing her direct beneficial ownership to 82,502 shares.

Summary

• Jannie Herchuk, a Director at Aspira Women's Health Inc. (AWHL), converted 8,437 restricted stock units (RSUs) into common stock.
• This conversion occurred on June 4, 2025, upon the vesting of the RSUs.
• The RSUs were part of a grant of 33,750 RSUs awarded to Ms. Herchuk on August 22, 2024.
• Following this transaction, Ms. Herchuk directly beneficially owns 82,502 shares of Aspira Women's Health Inc. Common Stock.
• The conversion price for these shares was $0, as it represents the vesting of previously granted equity compensation.

Sentiment

Score: 6

Explanation: The document reports a routine and expected equity compensation event (RSU vesting) for a director. While not directly indicative of operational performance, it reflects ongoing alignment of management interests with shareholders. There are no negative surprises or significant positive catalysts.

Positives

• The vesting and conversion of restricted stock units into common stock indicates a planned equity compensation event for a director, aligning management's interests with shareholders.
• An increase in direct beneficial ownership by a director, even through vesting, can be seen as a positive signal of continued commitment to the company.

Negatives

• No specific negative information is contained within this Form 4 filing, as it primarily reports a routine equity compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing, which is a disclosure of insider trading activity.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• This Form 4 filing does not contain any notable quotes or paraphrased statements from company management.

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation, which is common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive dynamics within the women's health sector.

Comparison to Industry Standards

• This document reports a standard equity compensation vesting event for a director. Such events are common practice across publicly traded companies globally as a means of aligning executive and director interests with shareholder value. There are no specific comparable companies or projects mentioned to assess against industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• This filing reports an equity compensation event for a director, which is a common type of related party transaction, but no other specific related party dealings are detailed.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock slightly increases the number of outstanding shares, but this is a routine part of equity compensation plans. It also shows continued alignment of a director's interests with shareholders through direct ownership.
• Employees/Management: This reflects the ongoing execution of the company's equity compensation program for its directors.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this Form 4 filing, beyond the completion of this specific RSU vesting.

Key Dates

Recommendation

Keywords

Aspira Women's Health, AWHL, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Common Stock, Director Ownership, Equity Compensation